Trevi TherapeuticsTRVI
TRVI
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 31
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
700% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 8 (+7) [Q1 2025]
381% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $2.23M
200% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 14
68% more capital invested
Capital invested by funds: $330M [Q4 2024] → $554M (+$225M) [Q1 2025]
66% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 32
25% more funds holding
Funds holding: 110 [Q4 2024] → 137 (+27) [Q1 2025]
2.2% more ownership
Funds ownership: 88.95% [Q4 2024] → 91.16% (+2.2%) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
221%
upside
Avg. target
$23
247%
upside
High target
$25
282%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Josh Schimmer | 282%upside $25 | Overweight Initiated | 1 Jul 2025 |
D. Boral Capital Jason Kolbert | 221%upside $21 | Buy Maintained | 2 Jun 2025 |
HC Wainwright & Co. Brandon Folkes | 221%upside $21 | Buy Initiated | 28 May 2025 |
Needham Serge Belanger | 266%upside $24 | Buy Reiterated | 20 May 2025 |
Financial journalist opinion
Based on 3 articles about TRVI published over the past 30 days
Positive
Zacks Investment Research
15 hours ago
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
NEW HAVEN, Conn. , July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts.
Neutral
GlobeNewsWire
2 weeks ago
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company's long-term investors.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn. , June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn. , June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 17,400,000 shares of its common stock at a public offering price of $5.75 per share, for total proceeds of $100 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn. , June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
Positive
Benzinga
1 month ago
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics to Participate in Upcoming June Conferences
NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.
Charts implemented using Lightweight Charts™